Miglustat Powder
NDC Package 76339-178-01
Package Information
Miglustat powders is miglustat is used for the long-term treatment of a certain rare genetic problem (Gaucher's disease). This formulation utilizes a powder delivery system. Marketed by Apothecon Pharmaceuticals Pvt Ltd, this product is identified by NDC 76339-178.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 76339 - Apothecon Pharmaceuticals Pvt Ltd
- 76339-178 -
- 76339-178-01 - 1 BAG in 1 DRUM / 1 BAG in 1 BAG / 4.999 kg in 1 BAG
- 76339-178 -
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (76339-178). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 76339-178-01 identifies a specific commercial package of 1 bag in 1 drum / 1 bag in 1 bag / 4.999 kg in 1 bag of Miglustat (UNFINISHED drug), a bulk ingredient labeled by Apothecon Pharmaceuticals Pvt Ltd. This powder is formulated for use and contains miglustat as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Apothecon Pharmaceuticals Pvt Ltd on October 26, 2021. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Miglustat is used for the long-term treatment of a certain rare genetic problem (Gaucher's disease). It works by decreasing the amount of a certain natural fatty substance (glucosylceramide) that builds up due to this condition. This can help improve symptoms of Gaucher's disease, such as tiredness, pain in the joints/bones, and a swollen liver or spleen.
How is this Apothecon Pharmaceuticals Pvt Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 76339017801. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.